IDEXX Laboratories stock price target raised to $775 by Stifel on growth outlook

Stifel has raised its price target for IDEXX Laboratories (IDXX) to $775 from $700, reiterating a Buy rating, driven by expectations of improving veterinary visits, durable pricing, and strengthening premium market positioning. This upgrade follows IDEXX's strong Q3 2025 financial results, which exceeded analyst expectations with EPS of $3.22 and revenue of $1.1 billion. Stifel revised key metrics upward, including a 'Street high' 2027 EPS estimate of $16.84 and increased 2026 recurring revenue growth projections, despite the stock currently trading above its InvestingPro Fair Value with a high P/E ratio.

Analysis

Stifel has raised its price target for IDEXX Laboratories (IDXX) to $775.00 from $700.00, maintaining a Buy rating, following the company's robust Q3 2025 financial results. IDEXX reported earnings per share of $3.22, surpassing projections by 2.55%, and revenue of $1.1 billion, exceeding expectations by 2.8%. This strong operational execution has contributed to heightened investor confidence.

The price target increase is underpinned by Stifel's updated thesis, which observed improvements in veterinary visits, durable pricing, and strengthening of IDEXX’s premium market positioning during the quarter. Consequently, Stifel revised nearly all key metrics upward, including a "Street high" 2027 EPS estimate of $16.84 and an increased 2026 worldwide Companion Animal Group (CAG) diagnostics recurring revenue growth projection to 8.8%.

Despite the optimistic outlook and strong performance, IDEXX currently trades at $719.79, representing a significant 50.86% return over the past year. The stock is valued above its InvestingPro Fair Value, carrying a high P/E ratio of 59.93, indicating a premium valuation relative to its earnings.

Key Decisions for Investors

• Investors should acknowledge IDEXX's strong operational performance and positive analyst sentiment, which supports its premium market positioning and growth trajectory.
• Given the stock's current valuation at a high P/E of 59.93 and trading above its InvestingPro Fair Value, investors should carefully assess entry points and potential for further multiple expansion.
• Monitor future veterinary visit trends, pricing durability, and the company's ability to consistently deliver "Street high" earnings estimates to justify its premium valuation.